scholarly journals Effects of Probiotics on Metabolic Syndrome: A Systematic Review of Randomized Clinical Trials

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 124 ◽  
Author(s):  
Carmen Tenorio-Jiménez ◽  
María José Martínez-Ramírez ◽  
Ángel Gil ◽  
Carolina Gómez-Llorente
Keyword(s):  
Systematic Review ◽  
Metabolic Syndrome ◽  
Randomized Clinical Trials ◽  
Healthy Lifestyle ◽  
Inflammatory Biomarkers ◽  
Beneficial Effects ◽  
Develop Type ◽  
Factor Α ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Growth Factor

The aim of this systematic review is to evaluate whether the use of probiotics has any effect on the components of metabolic syndrome (MetS) before patients develop type 2 diabetes. A qualitative systematic review, following the Cochrane methodology, and a comprehensive literature search of randomized controlled trials (RCTs) were conducted in PubMed and Scopus from inception until 4 July 2019. According to our inclusion criteria, nine clinical studies were finally analyzed, corresponding to six RCTs. Probiotics intake in patients with MetS resulted in improvements in body mass index, blood pressure, glucose metabolism, and lipid profile in some studies. Regarding inflammatory biomarkers, probiotics also positively affected the soluble vascular cell adhesion molecule 1 (sVCAM-1), interleukine-6 (IL-6), tumor necrosis factor α (TNF-α), vascular endothelial growth factor (VEGF), and thrombomodulin. Despite the diversity of the published studies, the intake of probiotics for patients with MetS may offer a discrete improvement in some of the clinical characteristics of the MetS and a decrease in inflammatory biomarkers. Nevertheless, these beneficial effects seem to be marginal compared to drug therapy and a healthy lifestyle and clinically non-relevant.

scholarly journals Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1761 ◽  
Author(s):  
Carmen Tenorio-Jiménez ◽  
María José Martínez-Ramírez ◽  
Isabel Del Castillo-Codes ◽  
Carmen Arraiza-Irigoyen ◽  
Mercedes Tercero-Lozano ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Animal Studies ◽  
Lactobacillus Reuteri ◽  
Healthy Lifestyle ◽  
Adult Patients ◽  
Inflammatory Biomarkers ◽  
Gastrointestinal Microbiome ◽  
Microbiome Composition ◽  
Beneficial Effects ◽  
Inflammatory Parameters

Previous studies have reported that probiotics may improve clinical and inflammatory parameters in patients with obesity and metabolic syndrome (MetS). Lactobacillus (L.) reuteri V3401 has shown promising results on the components of MetS in animal studies. We aimed to evaluate the effects of L. reuteri V3401 together with healthy lifestyle recommendations on adult patients with MetS. Methods: We carried out a randomized, crossover, placebo-controlled, single-center trial in which we included 53 adult patients newly diagnosed with MetS. Patients were block randomly allocated by body mass index (BMI) and sex to receive a capsule containing either the probiotic L. reuteri V3401 (5 × 109 colony-forming units) or a placebo once daily for 12 weeks. Anthropometric variables, biochemical and inflammatory biomarkers, as well as the gastrointestinal microbiome composition were determined. Results: There were no differences between groups in the clinical characteristics of MetS. However, we found that interleukin-6 (IL-6) and soluble vascular cell adhesion molecule 1 (sVCAM-1) diminished by effect of the treatment with L. reuteri V3401. Analysis of the gastrointestinal microbiome revealed a rise in the proportion of Verrucomicrobia. Conclusions: Consumption of L. reuteri V3401 improved selected inflammatory parameters and modified the gastrointestinal microbiome. Further studies are needed to ascertain additional beneficial effects of other probiotic strains in MetS as well as the mechanisms by which such effects are exerted.

The Effect of Soy and Soy Products Consumption on Inflammatory Biomarkers: Protocol for a Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Mahsa Rezazadegan ◽  
Fatemeh Mirjalili ◽  
Mohammad Hossein Rouhani
Keyword(s):  
Systematic Review ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Rank Correlation ◽  
Fixed Effect Model ◽  
Inflammatory Biomarkers ◽  
Sensitivity Analyses ◽  
Effect Model ◽  
Study Heterogeneity ◽  
Factor Α

Background: Inflammation is a process that occurs in early phase of recovery in which immune system recognizes and removes immunological stimuli. Many chronic diseases have inflammation based pathogenesis. Several studies used soy and soy products for reducing inflammatory biomarkers. Objectives: The purpose of the present systematic review and meta-analysis of randomized clinical trials is to determine the effects of soy and soy products on inflammatory biomarkers. Methods: The following databases will be investigated for randomized controlled trials published until October 2019 to evaluate the effects of soybean and soy products on the inflammatory biomarkers in healthy subjects and patients with high inflammatory biomarkers: PubMed, Scopus, ISI Web of Science and Google scholar.Two independent investigators (M.R and F.M) will screen the title and the abstract of included articles. Mean and standard deviation (SD) or standard error (SE) for outcomes will be extracted. The quality of studies will be assessed by Cochrane Risk of Bias Tool. STATA software will be used to do a standard statistical analysis. A subgroup analysis will be applied to find out potential sources of inter-study heterogeneity. A Random-effects model will be conducted to calculate pooled effect size. A fixed-effect model will be incorporated to estimate the between-subgroup heterogeneity. Moreover, sensitivity analyses, Egger's regression asymmetry test and Begg's rank-correlation methods will be conducted. Results: We will try to find a major number of articles about the effectiveness of soy and soy products on inflammatory biomarkers. Tumor necrosis factor α (TNF-α), interleukine 6 (IL-6), interleukine 2 (IL-2), interleukine 1-β (IL-1β), interferon-gamma (IFN-γ) and Interleukine 10 (IL-10) are considered to be the outcome. Conclusion: The findings of this systematic review and meta-analysis may provide evidence on the effectiveness and safety of soy and soy products for reducing inflammation.

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

The effect of soya consumption on inflammatory biomarkers: a systematic review and meta-analysis of clinical trials

2020 ◽  
pp. 1-12
Author(s):  
Mahsa Rezazadegan ◽  
Fatemeh Mirjalili ◽  
Cain C. T. Clark ◽  
Mohammad Hossein Rouhani
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Web Of Science ◽  
Meta Analysis ◽  
Inflammatory Biomarkers ◽  
Beneficial Effects ◽  
Isi Web Of Science ◽  
Subgroup Analyses ◽  
Study Heterogeneity ◽  
High Doses

Abstract Inflammation is a major cause of chronic diseases. Several studies have investigated the effects of soya intake on inflammatory biomarkers; however, the results are equivocal. The aim of this study was to conduct a systematic review and meta-analysis of clinical trials that evaluated the effect of soya consumption on inflammatory biomarkers. Medline, Scopus, ISI Web of Science and Google Scholar were systematically searched, up to and including May 2020, for clinical trials that evaluated the effects of soya and soya products on TNF-α, IL-6, IL-2, IL-1β and interferon γ (IFN-γ) in adults. A random effects method was used to calculate overall effects, and subgroup analyses were performed to discern probable sources of inter-study heterogeneity. A total of twenty-eight clinical trials were included. Although soya consumption reduced TNF-α (Hedges’ g = –0·28; 95 % CI –0·49, –0·07), it had no significant effect on IL-6 (Hedges’ g = 0·07, 95 % CI –0·14, 0·28), IL-2 (mean difference (MD) = –1·38 pg/ml; 95 % CI –3·07, 0·31), IL-1β (MD = –0·02 pg/ml; 95 % CI –0·08, 0·03) and IFN-γ (MD = 1685·82 pg/ml; 95 % CI –1604·86, 4976·50). Subgroup analysis illustrated a reduction in TNF-α in parallel designed studies, at dosages ≥100 mg of isoflavones, and in unhealthy subjects. The present study showed that high doses of isoflavones in unhealthy subjects may yield beneficial effects on TNF-α.

scholarly journals Probiotics supplementation and insulin resistance: a systematic review

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Bárbara Izabel Moraes Salles ◽  
Débora Cioffi ◽  
Sandra Roberta G. Ferreira
Keyword(s):  
Systematic Review ◽  
Insulin Resistance ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Metabolic Diseases ◽  
Healthy Lifestyle ◽  
Intestinal Barrier ◽  
Short Chain Fatty Acids ◽  
Intestinal Barrier Function ◽  
Medical Subject Headings

Abstract Background Research on intestinal microbiota has grown considerably, as well as the interest on probiotics’ supplementation effects on metabolism. Considering high prevalence rates of metabolic diseases linked by insulin resistance, we performed a systematic review of existing literature which addressed the role of probiotics in modulating insulin sensitivity in animals and humans. Methods This systematic review was based on PRISMA guidelines. Searches for original articles published in English from 1990 to January 2020 were made in the electronic database of PubMed from the National Library of Medicine, using Medical Subject Headings to identify longitudinal studies conducted in animals and humans which reported effects of probiotics in a variety of insulin resistance parameters. Results Overall, results from 27 probiotic interventions (Lactobacillus, Bifidobacterium, Clostridium and Akkermansia) indicated significant beneficial changes in insulin resistance measures in animal studies. Additionally, they improved lipid profile, inflammatory and oxidative markers, short-chain fatty acids production and microbiota composition. In seven clinical trials, samples and designs were heterogeneous. Five showed benefits in insulin resistance parameters and in two others no effect was detected. Conclusion Available data regarding the effects of certain probiotics do not guarantee sustained amelioration of insulin resistance in humans. Consistent beneficial results for intestinal barrier function, immune system and metabolism were reported in animals may encourage long-term randomized clinical trials in people with obesity and cardiometabolic risk. Whether supplementation with probiotics in combination with medications and/or prebiotics, associated with a healthy lifestyle, will prove useful to attenuate insulin resistance requires further investigation.

Effect of Cashew Nut on Lipid Profile: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 27 (5) ◽  
pp. 348-356 ◽  
Author(s):  
Mojgan Morvaridzadeh ◽  
Mahdi Sepidarkish ◽  
Farnaz Farsi ◽  
Abolfazl Akbari ◽  
Roghayeh Mostafai ◽  
...  
Keyword(s):  
Systematic Review ◽  
Lipid Profile ◽  
Fixed Effects ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Cochrane Library ◽  
Analysis Model ◽  
Beneficial Effects ◽  
Cashew Nut

Introduction: Nuts are one of the dietary components which appear to have beneficial effects on cardiovascular disease biomarkers. Studies demonstrate beneficial effects of cash­ews on serum lipids concentration, but results in the literature remain inconclusive. We conducted a review to examine the effects of cashew nut supplementation on serum lipid profile. Methods: Two reviewers independently searched PubMed, Web of Science, Cochrane Library, Scopus, and EMBASE electronic databases from inception until June 2019 without language limitation. Random- and fixed-effects models were used to calculate 95% confidence intervals (CI) for studies. Results: Six randomized clinical trials comprising 531 participants were included in this systematic review. Three studies were included in the meta-analysis model. There were no significant changes for total cholesterol (TC) (standardized mean difference [SMD]: –0.02, 95% CI: –0.32, 0.28), triglycerides (TG) (SMD: –0.01, 95% CI: –0.22, 0.20), high-density lipoprotein (HDL) cholesterol (SMD: 0.09, 95% CI: –0.16, 0.34), or low-density lipoprotein (LDL) cholesterol (SMD: –0.18, 95% CI: –0.75, 0.39). Conclusion: The results of this analysis demonstrate that treatment with cashew nut supplementation alone did not significantly change serum levels of LDL, HDL, TC, or TG.

Effect of resveratrol derivative BTM-0512 on high glucose-induced dysfunction of endothelial cells: role of SIRT1

2011 ◽  
Vol 89 (10) ◽  
pp. 713-722 ◽  
Author(s):  
Qiong Yuan ◽  
Lei Chen ◽  
Da-Xiong Xiang ◽  
Yuan-Jian Li ◽  
Chang-Ping Hu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Endothelial Cells ◽  
Tumor Necrosis Factor ◽  
High Glucose ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Vascular Endothelial ◽  
Beneficial Effects ◽  
Factor Α ◽  
Endothelial Growth Factor

Hyperglycemia impairs the function of endothelial cells. Sirtuin 1 (SIRT1) is involved in regulating the function of endothelial cells. Resveratrol, a polyphenol found in many plant species, exerts protective effects on endothelial cells through activation of SIRT1. The aims of this work were to explore whether BTM-0512, a novel derivative of resveratrol, is able to exert beneficial effects on high glucose-induced dysfunction of endothelial cells through regulation of SIRT1. We found that high glucose significantly impaired the function of endothelial cells as shown by reduced tube formation, cell migration, and cell adhesion concomitantly with downregulation of mRNA expression of SIRT1 and vascular endothelial growth factor as well as increased tumor necrosis factor-α release and reactive oxygen species production. These effects of high glucose were inhibited by pretreatment with BTM-0512. The beneficial effects of BTM-0512 on high glucose-induced cell dysfunction were abolished by splitomicin, a specific inhibitor of SIRT1. The regulatory effects of BTM-0512 on high glucose-induced changes in vascular endothelial growth factor mRNA expression and tumor necrosis factor-α release were also abolished by splitomicin. The results suggest that BTM-0512 exerts beneficial effects on high glucose-induced endothelial cell dysfunction through regulation of the SIRT1 – reactive oxygen species – vascular endothelial growth factor – tumor necrosis factor-α pathway.

Sign in / Sign up

Export Citation Format

Share Document